ArticleTranslational lung cancer research2025
Comparative survival outcomes between EGFR-wildtype and EGFR-mutant lung adenocarcinoma following neoadjuvant chemoimmunotherapy: a retrospective cohort study from national cancer center in China.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Significant improvement in overall survival with postoperative traditional Chinese medicine in stage I lung adenocarcinoma: a real-world retrospective cohort study.Translational lung cancer research · 2026Article
- Single-cell atlas reveals a pro-metastatic RELB+ neutrophil-myeloid subset underlying lymph node metastasis in EGFR-wildtype LUAD.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The efficacy of neoadjuvant chemoimmunotherapy (NCI) in resectable epidermal growth factor receptor-mutant (EGFR-mutant) lung adenocarcinoma (LUAD) remains controversial. This study aimed to compare the clinical efficacy, survival outcomes, and recurrence patterns between EGFR-wildtype and EGFR-mutant clinically stage I-III LUAD patients following NCI. Methods: This retrospective study enrolled 97 patients (65 in the EGFR-wildtype group and 32 in the EGFR-mutant group). After balancing baseline characteristics via propensity score matching (PSM) with a 2:1 ratio, perioperative outcomes, pathological response rates, survival rates, and recurrence patterns were compared between the two groups. Results: Post-PSM (EGFR-wildtype: n=50; EGFR-mutant: n=30), the EGFR-mutant group exhibited numerically similar rates of pathological complete response (pCR) (3.3% Conclusions: EGFR mutation status may not independently predict survival outcomes after NCI, it could influence recurrence patterns, suggesting a need for enhanced local control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.